MedImmune, the global biologics arm of AstraZeneca PLC, announced that it is restructuring its infectious disease and vaccines research, development and operations. This will result in the closure of MedImmune’s Mountain View, CA and Santa Clara, CA sites, and consolidation of its infectious disease and vaccines research and development activities to other existing sites. The changes are expected to be completed in 2014 to allow for a seamless transition of ongoing activities.
MedImmune’s Hayward, CA site will remain open with additional capabilities invested in the site.
{iframe}http://pressroom.medimmune.com/press-releases/2012/07/16/medimmune-to-streamline-vaccines-operations-in-california/{/iframe}